# A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

> **NCT02555644** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 70 (estimated)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Prexasertib
- **DRUG:** Cisplatin
- **DRUG:** Cetuximab
- **RADIATION:** Intensity Modulated Radiation Therapy

## Key facts

- **NCT ID:** NCT02555644
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-24
- **Primary completion:** 2019-01-14
- **Final completion:** 2019-01-14
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555644, "A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02555644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*